Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a revenue of 1.378 billion yuan in 2025, representing a year-on-year growth of 40.6%, and a net profit attributable to shareholders of 173.2 million yuan, reflecting a significant increase of 416% [7] - The company is positioned to benefit from the global competitive landscape in the model animal and preclinical CRO services, with a strong focus on antibody development integrated with AI technology [7] - The revenue from model animal sales reached 622 million yuan, up 59.9%, while preclinical CRO services generated 352 million yuan, up 75.2% [7] - The antibody development business generated 332 million yuan in revenue, marking a 42% increase, supported by the proprietary RenMice platform [7] - The company has established a robust AI model to enhance the efficiency of antibody development, which is expected to accelerate the release of potential candidates [7] - Revenue forecasts for 2026-2028 have been revised upwards, with expected revenues of 19.4 billion yuan and 25.5 billion yuan for 2026 and 2027, respectively [7] Financial Summary - Total revenue is projected to grow from 1.378 billion yuan in 2025 to 3.292 billion yuan by 2028, with a compound annual growth rate (CAGR) of approximately 29.15% [1][8] - The net profit attributable to shareholders is expected to increase from 173.2 million yuan in 2025 to 902.77 million yuan in 2028, indicating a strong growth trajectory [1][8] - The earnings per share (EPS) is forecasted to rise from 0.39 yuan in 2026 to 2.02 yuan in 2028, reflecting the company's improving profitability [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a total revenue of 1.38 billion RMB in 2025, representing a year-on-year growth of 40.6%, and a net profit attributable to shareholders of 173.2 million RMB, reflecting a significant increase of 416% [7] - The company is positioned to benefit from the global competitive landscape in the model animal and preclinical CRO services, with a notable increase in overseas revenue by 42% to 940 million RMB in 2025 [7] - The antibody development business is entering a rapid revenue generation phase, with revenues of 332 million RMB in 2025, up 42% year-on-year [7] - The integration of AI in antibody development is expected to enhance efficiency and reduce R&D risks, leveraging a vast database of antibody sequences [7] - The company has adjusted its revenue and net profit forecasts for 2026-2027 upwards, indicating strong growth potential [7] Financial Summary - Total revenue projections for 2026 and 2027 have been revised to 1.94 billion RMB and 2.55 billion RMB, respectively, with net profit estimates adjusted to 344.1 million RMB and 534.2 million RMB [1][8] - The company’s operating cash flow for 2025 was 370.25 million RMB, showing a 75% increase [7] - The gross margin for the model animal sales business was 80.4%, while the gross margin for the preclinical CRO services was 61.3% [7]

Group 1 - The core viewpoint of the news is that Baiaosaitu has successfully listed its H-shares on the Hong Kong Stock Exchange and has been included in the Hong Kong Stock Connect program, allowing eligible investors from mainland China to invest directly in its H-shares [1][3] - Following this announcement, Baiaosaitu's H-shares surged by 22.23% to HKD 35.08 per share, while its A-shares increased by 3.42% to CNY 52.6 per share, indicating strong market reaction [1] - The inclusion in the Hong Kong Stock Connect is seen as a significant milestone for the company, enhancing its capital accessibility, market recognition, and long-term investment value [1][3] Group 2 - Baiaosaitu, established in 2009, operates as a preclinical CRO and biopharmaceutical company, providing innovative animal models and preclinical drug development services based on its proprietary gene editing technology [2] - The company has developed a comprehensive platform for drug discovery and development, including the RenMice platform, which targets over a thousand potential drug targets [2] - Baiaosaitu has signed approximately 280 drug cooperation development, licensing, and transfer agreements, establishing a leading global repository of humanized mouse models and offering full-chain capabilities in preclinical pharmacology and efficacy research [3] Group 3 - The company aims to leverage the synergy between its A-share and H-share platforms to enhance its technological platform transformation, global business expansion, and long-term strategic implementation [3] - Baiaosaitu is committed to maintaining a technology innovation-driven approach, deepening its global collaboration network, and improving operational quality and communication with the capital market [3] - The company positions itself as a "global source of new drugs," contributing long-term value to the high-quality development of China's biopharmaceutical industry and global innovation [3]

Core Viewpoint - The A-share market experienced an overall decline on December 10, 2023, with more stocks falling than rising, although the Hainan Free Trade Zone concept emerged as a significant highlight [1][5][6]. Group 1: Market Performance - The A-share market saw major indices decline to varying degrees, with the retail, non-ferrous metals, automotive, and media sectors showing strength, while banking, power equipment, and computer sectors faced the largest declines [5][6]. - The Hainan Free Trade Zone concept led the market, with stocks like Luoniushan, Hainan Expressway, and Hainan Ruize hitting the daily limit, alongside several others rising [6]. Group 2: Notable Stocks - Moer Thread's stock price surged again, breaking the 700 yuan mark and reaching a new high, with an intraday increase of over 19%, making it the third highest stock in the A-share market after Cambrian and Kweichow Moutai [3][8]. - The newly listed stock Bai Ao Sai Tu saw its price rise by over 160% during the morning session, indicating strong market interest [10][11]. Group 3: Policy and Economic Development - The Hainan Provincial Committee of the Communist Party released suggestions for the 15th Five-Year Plan, emphasizing the enhancement of the "investment free trade port" brand and the establishment of a robust foreign investment service mechanism [6]. - The plan aims to promote significant foreign investment projects, improve trade quality, and facilitate the integration of domestic and foreign trade, while also enhancing living conditions for foreign visitors and talents [6].

Core Viewpoint - The article discusses the upcoming IPOs of two companies, Moer Technology and Baiaosaitu, highlighting their significance in the GPU and biotechnology sectors respectively [1][2]. Group 1: Moer Technology - Moer Technology is a leading player in the domestic GPU market and will become the "first domestic GPU stock" upon its listing [2]. - The IPO price for Moer Technology is set at 114.28 yuan per share, with a maximum subscription limit of 11,000 shares per account, requiring a market value of 110,000 yuan in the Shanghai market for full subscription [2]. - The company focuses on the research, design, and sales of GPUs and related products, aiming to provide computing acceleration platforms for AI, digital twins, and high-performance computing [2]. - Moer Technology has successfully launched four generations of GPU architectures and has a diverse product matrix covering various application fields, including AI computing, high-performance computing, and consumer entertainment [2][3]. - The company achieved revenues of 0.46 billion yuan, 1.24 billion yuan, and 4.38 billion yuan from 2022 to 2024, with net losses of -1.894 billion yuan, -1.703 billion yuan, and -1.618 billion yuan respectively [3]. Group 2: Baiaosaitu - Baiaosaitu has a maximum subscription limit of 7,500 shares per account, requiring a market value of 75,000 yuan in the Shanghai market for full subscription [4]. - The company operates as a preclinical CRO and biotechnology firm, providing innovative animal models and preclinical drug development services based on its proprietary gene editing technology [4]. - Baiaosaitu has developed a platform called RenMice for antibody discovery, targeting nearly a thousand potential drug targets, and has established partnerships with numerous well-known biotech and pharmaceutical companies [5]. - The company expects revenues of 5.34 billion yuan, 7.17 billion yuan, and 9.8 billion yuan from 2022 to 2024, with net losses of -602 million yuan, -383 million yuan, and a profit of 34 million yuan respectively [5].

百奥赛图（北京）医药科技股份有限公司 首次公开发行股票并在科创板上市 | 序号 | 文件名称 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1-41 | | 2 | 财务报表及审计报告 | 42-241 | | 3 | 审阅报告 | 242-325 | | 4 | 内部控制审计报告 | 326-339 | | 5 | 经注册会计师鉴证的非经常性损益明细表 | 340-356 | | 6 | 法律意见书 | 357-1203 | | 7 | 律师工作报告 | 1204-1552 | | 8 | 发行人公司章程（草案） | 1553-1616 | | 9 | 中国证监会同意本次发行注册的文件 | 1617-1618 | 招股意向书附录 中国国际金融股份有限公司 关于百奥赛图（北京）医药科技股份有限公司 首次公开发行股票并在科创板上市的 发行保荐书 保荐机构 （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 2025 年 11 月 1 关于百奥赛图（北京）医药科技股份有限公司 首次公开发行股票并在科创板上市的 发行保荐书 中国证券监督管理委员会、上海证券 ...

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has successfully registered its IPO on the Sci-Tech Innovation Board, marking a significant milestone for the company in its growth trajectory [1] Company Overview - Established in 2009, Baiaosaitu is a preclinical CRO and biotechnology company [1] - The company offers various innovative animal models and preclinical pharmaceutical research and development services based on its proprietary gene editing technology [1] Technology and Services - Baiaosaitu utilizes its self-developed RenMice fully human antibody mouse platform, which includes multiple series such as RenMab, RenLite, RenNano, RenTCR, and RenTCR-mimic [1] - The platform targets nearly a thousand potential drug targets in the human body for large-scale drug discovery and development [1] - The company has plans to transfer, license, or co-develop promising antibody molecules [1] IPO Journey - The IPO application for Baiaosaitu was accepted on June 20, 2023, and the company passed the review on September 24, 2023 [1] - The registration for the IPO was submitted on September 26, 2023 [1]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to undergo its IPO review on September 24, 2025, after a two-year wait on the Sci-Tech Innovation Board, highlighting its progress in the biopharmaceutical sector and its innovative "Thousand Mice Ten Thousand Antibodies" program [1][4]. Group 1: Company Overview - Baiaosaitu was established in 2009 and operates as a preclinical CRO and biotechnology company, providing innovative animal models and drug development services based on its proprietary gene editing technology [1]. - The company has developed the RenMice platform, which allows for large-scale drug discovery targeting nearly a thousand potential drug targets [1]. Group 2: IPO Process and Financial Performance - The company was accepted for its Sci-Tech Innovation Board IPO on June 20, 2023, and has undergone two rounds of inquiries prior to the upcoming review [4]. - Financial data shows that Baiaosaitu's revenue increased from approximately 534 million yuan in 2022 to 980 million yuan in 2024, with a turnaround to a net profit of approximately 33.54 million yuan in 2024 after previous losses [5]. - In the first half of 2023, the company achieved a revenue of 621 million yuan, a 51.27% increase year-on-year, and reported a net profit of approximately 47.99 million yuan, indicating a successful recovery from losses [6]. Group 3: Research and Development Challenges - The company has experienced a significant reduction in its R&D personnel, with the number of dedicated R&D staff dropping from 58 in 2022 to just 5 in 2024, raising concerns about its innovation capacity [7]. - Governance issues are also present, as the major shareholders, who are a married couple, control over 27% of the voting rights, which may impact decision-making processes [7]. Group 4: Fundraising and Strategic Direction - Baiaosaitu has reduced its planned fundraising amount from 1.893 billion yuan to 1.185 billion yuan for its IPO, focusing on early drug development services, antibody drug research, and clinical projects [7][8]. - The company asserts that this reduction in fundraising will not alter its strategic direction, as the core projects will still revolve around its main business and technology platforms [8].

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has finally received the opportunity for its IPO review after over two years of waiting on the Sci-Tech Innovation Board, with the Shanghai Stock Exchange's listing review committee scheduled to meet on September 24, 2025, to discuss the company's initial public offering [1] Company Overview - Established in 2009, Baiaosaitu is a preclinical CRO and biotechnology company that provides various innovative model animals and preclinical drug development services based on its self-developed gene editing technology [1] - The company utilizes its proprietary RenMice fully human antibody mouse platform for large-scale drug discovery and development targeting nearly a thousand potential drug targets, referred to as the "Thousand Mice Ten Thousand Antibodies" initiative [1] IPO Process and Financial Performance - Baiaosaitu was listed on the Hong Kong Stock Exchange under Rule 18A in 2022 and had its Sci-Tech Innovation Board IPO accepted on June 20, 2023, entering the inquiry stage on July 18, 2023, after undergoing two rounds of inquiries [3] - The company reported revenues of approximately 534 million yuan, 717 million yuan, and 980 million yuan for the years 2022 to 2024, with corresponding net profits of approximately -602 million yuan, -383 million yuan, and 33.54 million yuan [4] - In the first half of this year, Baiaosaitu achieved revenue of 621 million yuan, a year-on-year increase of 51.27%, and a net profit of approximately 47.99 million yuan, marking a turnaround from losses [4] Business Model and Collaborations - The "Thousand Mice Ten Thousand Antibodies" initiative has generated significant commercial interest, with the company forming partnerships with numerous well-known pharmaceutical companies, including Merck, Gilead, and Neurocrine, among others [3] - The company has established a stable core management and R&D team, with core business areas showing growth and R&D investments maintained at reasonable levels, indicating an expected gradual enhancement in profitability [5] Fundraising and Strategic Direction - Baiaosaitu has reduced its initial fundraising target from 1.893 billion yuan to 1.185 billion yuan, with the funds aimed at early drug development service platform construction, antibody drug research and evaluation projects, and working capital [5][6] - The company emphasizes that the reduction in fundraising scale will not alter its strategic direction, as core fundraising projects will still focus on its main business and technology platform [6]

Core Insights - The company Baiaosaitu has made significant progress in the development of the innovative oncology drug IDE034, which targets multiple cancers such as lung and colorectal cancer, with plans to submit a clinical trial application in the US by Q4 of this year [1] Group 1: Drug Development - IDE034 is a dual-target antibody-drug conjugate (ADC) that can simultaneously recognize two tumor markers, B7H3 and PTK7, enhancing precision in targeting cancer cells and improving treatment efficacy and safety [1] - The drug utilizes Baiaosaitu's proprietary linker and payload platform BLD1102, which synergizes with IDEAYA's related technologies for stronger clinical outcomes [1] - The potential total transaction value for the licensing of the B7H3/PTK7 dual-target ADC pipeline to IDEAYA is nearly RMB 3 billion [1] Group 2: Company Capabilities - Baiaosaitu has developed the RenLite fully human antibody platform, which effectively avoids light and heavy chain mismatches, increasing the success rate of drug development [2] - The company also has the RenNano platform for generating fully human nanobodies, providing flexible design components for various advanced medical fields [2] - Baiaosaitu is recognized as a leading antibody drug development platform in China, with over one million antibody molecules with development potential [2] Group 3: Financial Performance - In the first half of this year, Baiaosaitu invested RMB 209 million in R&D, a year-on-year increase of 29.3% [3] - The company has accumulated 195 authorized patents and submitted 496 patent applications, with 80 new licensing agreements signed, a 60% increase compared to the same period last year [3] - Baiaosaitu achieved a revenue of RMB 621 million in the first half of 2025, representing a year-on-year growth of 51.3%, with nearly 70% of revenue coming from overseas partnerships [3]